The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

Article

Abstract: Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging r

Palabras claves:

CD6, Clinical trial, Itolizumab, Phase I, Rheumatoid Arthritis

Autores:

Aira L.E., Ávila Y., Barrese Y., Carmen Elena Viada, Gómez J.A., Hernández I.M., Hernández M.V., Hernández P., López A.M., Martínez J.P., Milera J.M., Molinero C., Montero E., Moreno E., Prada D.M., Reyes Y., Rodríguez P.C., Torres R.

Fuentes:

scopus